PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagement Findings support continued development of PrimeC's multi-target approach in Alzheimer's disease June 25, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive

Gilead’s Trodelvy can now be used as a monotherapy and in combination with Merck’s Keytruda to treat certain patients with triple-negative breast cancer. The FDA has given its go-ahead to Gilead’s anti-TROP-2 antibody-drug conjugate Trodelvy as a frontline option for two specific triple-negative breast cancer indications. With the approvals, announced Wednesday, Trodelvy can now be used as a monotherapy for patients with unresectable locally advanced or metastatic triple-negative breast cancer

Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeutic TKI resistance. June 25, 2026 -- Racura Oncology Limited (ASX: RAC), a clinical-stage biopharmaceutical company developing new small molecule based approaches to cancer treatment, today announced tha

June 25, 2026 -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its partner company with Aditum Bio, Oblenio Bio (“Oblenio”), has successfully closed an oversubscribed $62 million Series B financing round. The round was led by Pfizer Ventures, with participation from Deep Track Capital, GV, and founding investor Aditum Bio. This milestone significantly advances the clinical development of LBL‑051, Oblenio’s sole asset – a CD19×BCMA×CD

Favourable safety pro marked contrast to traditional inotropic therapeutics AC01 showed rapid and sustained numerical improvements in cardiac output, structure and function June 25, 2026 – AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, today announced the publication in The Lancet of results from its Phase 1b/2a GOAL-HF1 study evaluating AC01, a first-in-class, oral calcium-sensitising contractile agent, in patients with heart failure with r

Study met its primary endpoint, demonstrating statistically significant and clinically relevant improvements in ADHD symptoms in adults with ADHD and comorbid anxiety taking centanafadine compared to those taking placebo Centanafadine is currently under Priority Review by the FDA for the treatment of ADHD in children, adolescents, and adults, with a target action date of July 24, 2026 PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka

- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis - June 24, 2026 -- Cognition Therapeutics, Inc.， (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, today announced that it received written feedback from the U.S. Food and Drug Administration (FDA) following its recent meeting. The FDA agreed

June 23, 2026 -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) of China has cleared the clinical trial application for its innovative LILRB4/CD3 targeting T Cell Engager (TCE) bispecific antibody (R&D code: 6MW5311), for the treatment of hematologic malignancies, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myel

June 24, 2026 EQT Life Sciences joins new investors Frazier Life Sciences, Forbion, Monograph and Wellington Management, alongside existing investors LifeArc, Oxford Science Enterprises and Oxford University Innovation, in RQ Bio's oversubscribed USD 115 million Series A financing RQ Bio is developing antibody therapies to prevent seasonal influenza in high-risk and immunocompromised populations, with the Series A supporting its clinical progression and broader infectious disease pipeline As

Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral CRAC channel inhibitor CM5480 to IND clearance expected mid-2027 Anticipated cash runway into 2H 2027 with upfront proceeds June 24, 2026 -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calciu